Literature DB >> 1536697

Drug-induced gallbladder disease. Incidence, aetiology and management.

P P Michielsen1, H Fierens, Y M Van Maercke.   

Abstract

A great variety of drugs is reported to induce gallbladder disease by various pathogenetic mechanisms. Early epidemiological studies indicated a doubled risk of gallbladder disease in women taking oral contraceptives. More recent studies, however, have failed to confirm those findings; these conflicting results might be explained by the different methods used to define gallbladder disease. It was shown that the lithogenic index of the bile is increased during intake of oral contraceptives. Estrogens cause hypersecretion of cholesterol in bile, due to increase in lipoprotein uptake by the hepatocyte. Progesterone inhibits acyl coenzyme A-cholesterol acyl transferase (ACAT) activity, causing delayed conversion of cholesterol to cholesterol esters. Of the lipid lowering drugs, only clofibrate has been shown to increase the risk for gallstone formation. The other fibric acid derivatives have similar properties, but clinical experience is not as extensive. They seem to be inhibitors of the ACAT enzyme system, thereby rendering bile more lithogenic. Conflicting epidemiological data exist regarding the induction of acute cholecystitis by thiazide diuretics. Ceftriaxone, a third-generation cephalosporin, is reported to induce biliary sludge in 25 to 45% of patients, an effect which is reversible after discontinuing the drug. The sludge is occasionally a clinical problem. It was clearly demonstrated that this sludge is caused by precipitation of the calcium salt of ceftriaxone excreted in the bile. Long term use of octreotide is complicated by gallstone formation in approximately 50% of patients after 1 year of therapy, due to gallbladder stasis. Hepatic artery infusion chemotherapy by implanted pump is shown to be associated with a very high risk of chemically induced cholecystitis. Prophylactic cholecystectomy at the time of pump implantation is therefore advocated. Some drugs, such as erythromcyin or ampicillin, are reported to cause hypersensitivity-induced cholecystitis. Furthermore, there are reports on the influence of cyclosporin, dapsone, anticoagulant treatment, and narcotic and anticholinergic medication in causing gallbladder disease.

Entities:  

Mesh:

Year:  1992        PMID: 1536697     DOI: 10.2165/00002018-199207010-00005

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  102 in total

1.  Thrombosis with low-estrogen oral contraceptives.

Authors:  P D Stolley; J A Tonascia; M S Tockman; P E Sartwell; A H Rutledge; M P Jacobs
Journal:  Am J Epidemiol       Date:  1975-09       Impact factor: 4.897

2.  [Erythromycin caused liver injury and gallbladder inflammation].

Authors:  G Alemayehu; I Näslund
Journal:  Lakartidningen       Date:  1990-09-12

3.  ACUTE CHOLECYSTIC DISEASE.

Authors:  E S Judd; J R Phillips
Journal:  Ann Surg       Date:  1933-10       Impact factor: 12.969

4.  Reversible ceftriaxone-associated biliary pseudolithiasis in children.

Authors:  U B Schaad; J Wedgwood-Krucko; H Tschaeppeler
Journal:  Lancet       Date:  1988-12-17       Impact factor: 79.321

5.  Effects of clofibrate and of an estrogen-progestin combination on fasting biliary lipids and cholic acid kinetics in man.

Authors:  D Pertsemlidis; D Panveliwalla; E H Ahrens
Journal:  Gastroenterology       Date:  1974-04       Impact factor: 22.682

6.  Posttraumatic acalculous cholecystitis.

Authors:  I Mandelbaum; R M Palmer
Journal:  Arch Surg       Date:  1968-10

7.  Transient formation of precipitations in the gallbladder associated with ceftriaxone therapy.

Authors:  U B Schaad; H Tschäppeler; M J Lentze
Journal:  Pediatr Infect Dis       Date:  1986 Nov-Dec

8.  Chemical cholecystitis associated with hepatic artery infusion chemotherapy.

Authors:  C H Carrasco; P C Freeny; V P Chuang; S Wallace
Journal:  AJR Am J Roentgenol       Date:  1983-10       Impact factor: 3.959

9.  Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile.

Authors:  W C Duane; D B Hunninghake; M L Freeman; P A Pooler; L A Schlasner; R L Gebhard
Journal:  Hepatology       Date:  1988 Sep-Oct       Impact factor: 17.425

10.  Acute acalculous cholecystitis in the critically ill patient.

Authors:  R Orlando; E Gleason; A D Drezner
Journal:  Am J Surg       Date:  1983-04       Impact factor: 2.565

View more
  7 in total

1.  Ceftriaxone associated nephrolithiasis: a prospective study in 284 children.

Authors:  Masoumeh Mohkam; Abdollah Karimi; Atoosa Gharib; Hamid Daneshmand; Alireza Khatami; Nozar Ghojevand; Mostafa Sharifian
Journal:  Pediatr Nephrol       Date:  2007-01-17       Impact factor: 3.714

2.  Research Letter: Anticholinergic Drugs and the Gallbladder -A Neglected Effect?

Authors:  Gary D Friedman; Ninah Achacoso; Laurel A Habel
Journal:  Perm J       Date:  2017

3.  Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population.

Authors:  F X Caroli-Bosc; P Le Gall; P Pugliese; B Delabre; C Caroli-Bosc; J F Demarquay; J P Delmont; P Rampal; J C Montet
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

4.  Potential effect of cyclosporin A in formation of cholesterol gallstones in pediatric liver transplant recipients.

Authors:  S Cao; K Cox; S S So; W Berquist; S P Lee; W G Haigh; W Concepcion; H Monge; C O Esquivel
Journal:  Dig Dis Sci       Date:  1997-07       Impact factor: 3.199

5.  [Painless jaundice after holidays in Tanzania].

Authors:  R R Plentz; H Lenzen; M P Manns; J S Bleck
Journal:  Internist (Berl)       Date:  2005-10       Impact factor: 0.743

6.  Definitions, pathophysiology, and epidemiology of acute cholangitis and cholecystitis: Tokyo Guidelines.

Authors:  Yasutoshi Kimura; Tadahiro Takada; Yoshifumi Kawarada; Yuji Nimura; Koichi Hirata; Miho Sekimoto; Masahiro Yoshida; Toshihiko Mayumi; Keita Wada; Fumihiko Miura; Hideki Yasuda; Yuichi Yamashita; Masato Nagino; Masahiko Hirota; Atsushi Tanaka; Toshio Tsuyuguchi; Steven M Strasberg; Thomas R Gadacz
Journal:  J Hepatobiliary Pancreat Surg       Date:  2007-01-30

7.  Daclatasvir and Asunaprevir Combination Therapy-induced Hepatitis and Cholecystitis with Coagulation Disorder due to Hypersensitivity Reactions.

Authors:  Yuichi Miyashima; Yuichi Honma; Koichiro Miyagawa; Shinji Oe; Michio Senju; Michihiko Shibata; Masaaki Hiura; Shintaro Abe; Masaru Harada
Journal:  Intern Med       Date:  2016-12-15       Impact factor: 1.271

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.